Tissue transglutaminase (TG2) activity has been implicated in inflammatory disease processes such as Celiac disease, infectious diseases, cancer, and neurodegenerative diseases, such as Huntington's disease. Furthermore, four distinct biochemical activities have been described for TG2 including protein crosslinking via transamidation, GTPase, kinase and protein disulfide isomerase activities. Although the enzyme plays a complex role in the regulation of cell death and autophagy, the molecular mechanisms and the putative biochemical activity involved in each is unclear. Therefore, the goal of the present study was to determine how TG2 modulates autophagy and/or apoptosis and which of its biochemical activities is involved in those processes. To address this question, immortalized embryonic fibroblasts obtained from TG2 knock-out mice were reconstituted with either wild-type TG2 or TG2 lacking its transamidating activity and these were subjected to different treatments to induce autophagy or apoptosis. We found that knock out of the endogenous TG2 resulted in a significant exacerbation of caspase 3 activity and PARP cleavage in MEF cells subjected to apoptotic stimuli. Interestingly, the same cells showed the accumulation of LC3 II isoform following autophagy induction. These findings strongly suggest that TG2 transamidating activity plays a protective role in the response of MEF cells to death stimuli, because the expression of the wild-type TG2, but not its transamidation inactive C277S mutant, resulted in a suppression of caspase 3 as well as PARP cleavage upon apoptosis induction. Additionally, the same mutant was unable to catalyze the final steps in autophagosome formation during autophagy. Our findings clearly indicate that the TG2 transamidating activity is the primary biochemical function involved in the physiological regulation of both apoptosis and autophagy. These data also indicate that TG2 is a key regulator of cross-talk between autophagy and apoptosis.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00726-011-0899-xDOI Listing

Publication Analysis

Top Keywords

transamidating activity
16
tg2
12
tg2 transamidating
12
autophagy
8
apoptosis autophagy
8
biochemical activities
8
wild-type tg2
8
autophagy apoptosis
8
parp cleavage
8
mef cells
8

Similar Publications

Homogeneous antibody-drug conjugates (ADCs) exhibit significantly improved pharmacological properties compared to their heterogeneous counterparts. Site-specific conjugation of the payload to the IgG required for homogeneity can be achieved using enzymes. One example is microbial transglutaminase (MTGase), which can selectively perform transamidation on the Q295 residue of human Fc when N297 glycans are removed.

View Article and Find Full Text PDF

A metal-free and mild cleavage of tertiary -methoxybenzyl amides (PMB -amide) under photoredox conditions is developed using Mes-Acr-PhBF and Selectfluor to activate the electron-rich benzylic C-H bond of the PMB moiety. The resulting acyl fluoride intermediate is versatile and facilitates a one-pot transamidation of the PMB -amide. The value of this protocol is highlighted by performing the chemoselective activation of the PMB -amide in bifunctional molecules containing more reactive functionalities than the amide.

View Article and Find Full Text PDF

Transglutaminase 1: Emerging Functions beyond Skin.

Int J Mol Sci

September 2024

Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 0C7, Canada.

Transglutaminase enzymes catalyze Ca- and thiol-dependent posttranslational modifications of glutamine-residues that include esterification, hydrolysis and transamidation, which results in covalent protein-protein crosslinking. Among the eight transglutaminase family members in mammals, transglutaminase 1 (TG1) plays a crucial role in skin barrier formation via crosslinking and insolubilizing proteins in keratinocytes. Despite this established function in skin, novel functions have begun merging in normal tissue homeostasis as well as in pathologies.

View Article and Find Full Text PDF

TGM1/3-mediated transamidation of Exo70 promotes tumor metastasis upon LKB1 inactivation.

Cell Rep

August 2024

Cancer Research Center, School of Medicine, Xiamen University, Xiamen 361102, China. Electronic address:

Article Synopsis
  • Exo70 is a vital component of the exocyst complex that aids in cancer cell movement and the remodeling of the extracellular matrix, making it a potential drug target in cancer treatment.
  • Researchers found that Exo70 undergoes a specific modification called transamidation that enhances its interaction with other proteins necessary for cancer metastasis.
  • Cantharidin, an FDA-approved drug, can inhibit this modification, which could help slow down tumor cell migration and invasion, particularly in cancers with inactivated LKB1.
View Article and Find Full Text PDF

Transglutaminase 2-mediated histone monoaminylation and its role in cancer.

Biosci Rep

August 2024

Molecular, Cellular, and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH 43210, U.S.A.

Transglutaminase 2 (TGM2) has been known as a well-characterized factor regulating the progression of multiple types of cancer, due to its multifunctional activities and the ubiquitous signaling pathways it is involved in. As a member of the transglutaminase family, TGM2 catalyzes protein post-translational modifications (PTMs), including monoaminylation, amide hydrolysis, cross-linking, etc., through the transamidation of variant glutamine-containing protein substrates.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!